Investor Updates

20. November 2009
European medical advisory committee does not recommend approval of Avastin for deadly form of brain cancer
Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting ... mehr

20. November 2009
ACTEMRA Improves Signs and Symptoms in Children with Systemic Onset Juvenile Idiopathic Arthritis (sJIA)
Roche announced today that ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) successfully met its primary endpoint in ... mehr

18. November 2009
US FDA issues complete response letter for Rituxan/MabThera for chronic lymphocytic leukaemia
Roche announced today that the US Food and Drug Administration (FDA) issued a complete response to Genentech, a wholly-owned ... mehr

18. November 2009
Invitation to Roche investor science event from SABCS 2009
We kindly invite investors and analysts to participate in a conference call to discuss new clinical data and results presented ... mehr

18. November 2009
Roche announces start of new atherosclerosis study (dal-PLAQUE 2) for dalcetrapib
Roche today presented new preclinical data further supporting the differentiation of its novel cholesteryl ester transfer ... mehr

17. November 2009
Applications to allow Avastin to be combined with commonly used chemotherapies in advanced breast cancer submitted to FDA
Roche announced today that Genentech, a wholly-owned member of the Roche Group, has submitted two supplemental Biologics License ... mehr

16. November 2009
FDA Grants Emergency Use Authorization to Roche's Assay for 2009 H1N1 Influenza Virus
Roche announced today that it's RealTime ready Influenza A/H1N1 Detection Set for the 2009 H1N1 influenza virus has received ... mehr

10. November 2009
Roche reports positive Phase II results with potential first-in-class treatment for the negative symptoms of schizophrenia
Roche today reports results from a 320 patient phase II proof-of-concept study with it’s investigational glycine transporter-1 ... mehr

09. November 2009
Invitation to Roche investor science event from ASH 2009 - Conference call on 8 December 2009
mehr

09. November 2009
Anti-Malignancy Agent Avastin Obtained Approval for Additional Indication of Non-Small Cell Lung Cancer
Please find attached a press release issued by Chugai in Japan mehr

29. Oktober 2009
First Phase III clinical trial of Roche`s weekly taspoglutide meets primary end-point of change in HbA1c
Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus ... mehr

22. Oktober 2009
Phase III trial underway to investigate infusion-free administration of Herceptin for women with HER2-positive breast cancer
Roche and Halozyme Therapeutics announced today that a new subcutaneous formulation of Herceptin using Halozyme’s Enhanze ... mehr

19. Oktober 2009
Genentech and Biogen Idec Receive a Complete Response from FDA for Earlier Use of Rituxan for Rheumatoid Arthritis
Please find attached a press release issued by Genentech and Biogen Idec in the US with respect to the approval of Rituxan ... mehr

17. Oktober 2009
ACTEMRA inhibits progression of joint destruction in RA patients by over 80% compared to methotrexate alone
Two-year data from the LITHE study, being presented at the American College of Rheumatology, show that, with long-term use, ... mehr

16. Oktober 2009
Anti-Malignancy Agent/Anti-VEGF Humanized Monoclonal Antibody, Avastin Application for Approval of Additional Indication of Breast Cancer
Please find enclosed a press release by Chugai mehr

15. Oktober 2009
Roche reports further accelerated sales growth in third quarter
Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in ... mehr

07. Oktober 2009
Reminder: Roche's Third Quarter Sales 2009 Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

05. Oktober 2009
Two Phase III studies of Lucentis show early and sustained improvement in vision in patients with retinal vein occlusion
Genentech, Inc., a wholly-owned member of the Roche Group yesterday announced results from two Phase III studies of Lucentis® ... mehr

30. September 2009
RoACTEMRA filed in Europe for the Inhibition of Joint Damage and Improvement in Physical Function in Rheumatoid Arthritis
Roche announced today that it has submitted a filing to the European health authorities (the European Medicines Agency) to ... mehr

25. September 2009
Roche provides update on early-stage breast cancer study with Avastin
Roche has been informed by the National Cancer Institute and US Eastern Cooperative Oncology Group (ECOG) that they have suspended ... mehr

24. September 2009
Herceptin provides impressive survival benefit for patients with high levels of HER2 in their stomach cancer
A detailed analysis of the Phase III ToGA study announced today revealed an unprecedented survival benefit for patients whose ... mehr

24. September 2009
Continuous improvements in animal welfare within Roche Research
Roche announced the winners of its global 3Rs Award Program - a unique and innovative program that helps to reduce and limit ... mehr

24. September 2009
Anti-Cancer Agent Xeloda and Avastin Obtained Approval for Additional Indication of Colorectal Cancer
Please find enclosed a press release by Chugai mehr

23. September 2009
Adding Xeloda to standard chemotherapy before surgery helps to eradicate tumours in patients with early breast cancer
Results from the ABCSG 24 trial presented today at the joint 15th ECCO and 34th ESMO 2009 congress, Berlin, Germany showed ... mehr

23. September 2009
From inoperable disease to potentially life saving surgery - new Avastin data gives hope to colorectal cancer patients with liver metastases
New data from several studies presented at ECCO 151 and ESMO 342 confirm unique benefits of Avastin (bevacizumab) and Xeloda ... mehr

23. September 2009
Roche announces results from two early studies which show promise for patients with malignant melanoma
New data from phase II Avastin study and a phase I extension study of highly selective BRAF inhibitor mehr

23. September 2009
Phase IV lung cancer study confirms the safety and outstanding efficacy benefit of Avastin-based therapy in a 'real world' setting.
Key data from four presentations at the joint ECCO 15 and ESMO 34 congress strongly support the clinical benefit of Avastin ... mehr

21. September 2009
Reminder: Roche Investor Science Event: Conference Call from ECCO ESMO 2009 - Friday, September 25th, 2009
We are pleased to invite you to a Conference Call to discuss new data on Roche’s oncology products and pipeline being ... mehr

18. September 2009
Antineoplastic Agent / Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, Tarceva
Application for Approval of Additional Indication of Pancreatic Cancer mehr

17. September 2009
Study shows MabThera maintenance treatment delays disease progression in patients with incurable lymphoma
Results show patients treated with MabThera as initial and follow-on therapy stay in remission for longer. Roche announced ... mehr

14. September 2009
Roche's Third Quarter Sales 2009 Conference Call
Roche will publish its Sales Results for the 3rd Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

13. September 2009
Two new studies report increased survival rates in Tamiflu-treated patients with avian flu (H5N1) and severe seasonal flu
53% of patients with H5N1 infection survived when treated with Tamiflu compared with 12% of untreated patients. Rate of death ... mehr

11. September 2009
Roche Investor Science Event: Conference Call from ECCO ESMO 2009 - Friday, September 25th, 2009
We are pleased to invite you to a Conference Call to discuss new data on Roche’s oncology products and pipeline being ... mehr

08. September 2009
Roche announces new Corporate Executive Committee
William M. Burns, Juergen Schwiezer and Jonathan Knowles to retire – Pascal Soriot appointed COO Pharma Division and ... mehr

03. September 2009
Roche recognised as new Super Sector Leader in Dow Jones Sustainability Index
Roche (SIX: RO, ROG; OTCQX: RHHBY) has been rated as the new Super Sector Leader in Healthcare on the Dow Jones Sustainability ... mehr

03. September 2009
MabThera approved in Europe for use in patients with previously-treated chronic lymphocytic leukaemia
Roche announced today that the European Commission has approved MabThera (rituximab) for use in patients with relapsed or ... mehr

01. September 2009
Roche receives CE Mark certification for cobas 8000 modular analyzer series
Roche announced today that the CE Mark certification for cobas 8000 modular analyzer series has been granted allowing commercial ... mehr

31. August 2009
FDA Approves Valcyte (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants
Plus new oral solution offers dosing flexibility for pediatric patients. Roche announced today that the U.S. Food and Drug ... mehr

31. August 2009
Roche and Lonza Announce Opt-in for Singapore Manufacturing Facility
Roche and Lonza announced today that Genentech Singapore Pte. Ltd. (“Genentech Singapore”), a wholly-owned member ... mehr

18. August 2009
Avastin plus commonly used chemotherapies improves time without the disease getting worse in women with previously treated advanced breast cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a Phase III study of Avastin (bevacizumab) in combination with a range ... mehr

05. August 2009
Roche Continents takes place for the third time
For the third time, Roche and the Salzburg Festival have invited 100 students to take part in "Roche Continents". ... mehr

03. August 2009
Avastin approved in US for the most common type of kidney cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) plus interferon ... mehr

01. August 2009
Phase III study showed Tarceva helped patients with advanced non-small cell lung cancer live longer when used immediately after initial chemotherapy
Roche today announced that patients with advanced non-small cell lung cancer (NSCLC) who received Tarceva (erlotinib) immediately ... mehr

31. Juli 2009
FDA accepts complete response resubmission for ACTEMRA (tocilizumab)
Roche announced today that the U.S. Food & Drug Administration (FDA) has accepted the resubmission for the ACTEMRA (tocilizumab) ... mehr

30. Juli 2009
Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein Occlusion
Roche announced today that the Phase III study CRUISE showed Lucentis (ranibizumab injection) improved vision in patients ... mehr

29. Juli 2009
European commission approves broader label for Avastin allowing combination with docetaxel for the first-line treatment of advanced (metastatic) breast cancer
More patients with advanced breast cancer could benefit from Avastin as a result of a broader label allowing Avastin to be ... mehr

28. Juli 2009
Genentech Announces Appointment of Sandra J. Horning, M.D., to Senior Vice President, Global Head, Clinical Development Hematology/Oncology
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the appointment of ... mehr

28. Juli 2009
Roche and Google.org Start Initiative for Early Discovery of New Diseases
Roche Applied Science and Google.org recently started a joint project to demonstrate the feasibility of developing a multidisciplinary ... mehr

24. Juli 2009
MabThera receives positive opinion in Europe for treating patients whose chronic lymphocytic leukaemia returns
Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation ... mehr

24. Juli 2009
Full reconciliation of Chugai interim results into IFRS
Following the publication of Chugai’s official 2009 interim results, Roche offers this investor update which reconciles ... mehr

23. Juli 2009
Double-digit increase in sales, operating profit and Core EPS
Integration of Genentech progressing rapidly; full-year outlook raised; Group sales up 2 billion to 24 billion Swiss francs, ... mehr

22. Juli 2009
Reminder: Roche's Half Year Results for 2009
Roche will publish its Half Year Results for 2009 prior to the opening of the Swiss Stock Exchange on July 23 at 7.00 CET ... mehr

22. Juli 2009
Chugai Files NDA for a Renal Anemia Agent R744
Please find enclosed a press release by Chugai. mehr

21. Juli 2009
Roche Diagnostics showcases new technology at Clinical Lab Expo
Roche Diagnostics is featuring a diverse portfolio of solutions designed to help healthcare facilities and reference labs ... mehr

20. Juli 2009
Xeloda in combination with oxaliplatin shown to be effective in early colon cancer
Roche announced today results from the international phase III study NO16968 (XELOXA), investigating oral Xeloda in combination ... mehr

13. Juli 2009
New data from phase III SATURN study shows Tarceva improves overall survival when used immediately after initial chemotherapy in patients with advanced lung cancer
Roche announced today that SATURN, a pivotal Phase III study, met a key secondary endpoint of extending overall survival in ... mehr

02. Juli 2009
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Roche announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured ... mehr

01. Juli 2009
Roche launches novel program to ease Tamiflu access to developing economies
Roche today announced the initiation of the Tamiflu Reserves Program (TRP) for developing economies. The program, which is ... mehr

26. Juni 2009
European regulator gives positive opinion for the use of Avastin in combination with docetaxel for the first-line treatment of advanced breast cancer
Physicians will be able to offer patients more Avastin-based treatment options. Patients with advanced (metastatic) breast ... mehr

26. Juni 2009
Roche Files MabThera as a First-line Biologic Treatment for Rheumatoid Arthritis in Europe
Roche announced today that it has submitted a combined filing to the European health authorities (the European Medicines Agency) ... mehr

23. Juni 2009
Roche's Half Year Results for 2009
Roche will publish its Half Year Results for 2009 prior to the opening of the Swiss Stock Exchange on July 23 at 7.00 CET ... mehr

11. Juni 2009
New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis
RA patients with enhanced response identified. New data show for the first time that a course of 2 infusions of MabThera 1000mg ... mehr

11. Juni 2009
Reminder: Roche Investor Science Event: Conference call from EULAR 2009
We are pleased to invite you to a Conference Call to discuss new data on our Rheumatoid Arthritis portfolio being presented ... mehr

11. Juni 2009
Reminder: Invitation to Roche Accounting Teleconference
We are pleased to invite you to an accounting conference call followed by Q&A on the impact of the Genentech transaction ... mehr

10. Juni 2009
New data reinforces long-term efficacy of ACTEMRA in rheumatoid arthritis across all patient population types
Up to 56% of patients with active rheumatoid arthritis (RA) treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the ... mehr

09. Juni 2009
Roche to commence phase III trials with innovative treatment designed to lower cardiovascular risk in diabetes patients with recent heart attack
Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 ... mehr

08. Juni 2009
Invitation to Roche Accounting Teleconference
We are pleased to invite you to an accounting conference call followed by Q&A on the impact of the Genentech transaction ... mehr

05. Juni 2009
Reminder: Roche investor science event from ADA 2009
We kindly invite investors and analysts to participate in a conference call that will be held during the American Diabetes ... mehr

02. Juni 2009
IMPACT study shows longer Valcyte treatment provides better protection against cytomegalovirus (CMV) disease
New Phase III study results presented for the first time today at the ninth annual American Transplant Congress 2009 (ATC) ... mehr

01. Juni 2009
Encouraging first data on new targeted treatment for patients with melanoma - the deadliest form of skin cancer
Roche announced today results from a phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for ... mehr

31. Mai 2009
Herceptin landmark study (ToGA) reveals unprecedented survival benefit in HER2-positive stomach cancer
Data from the ToGA study presented today at the American Society for Clinical Oncology Annual Meeting in Orlando, Florida ... mehr

30. Mai 2009
Phase III study showed patients lived longer without advanced lung cancer progressing when Tarceva was added to Avastin as first-line maintenance therapy
Roche today announced that a Phase III study (ATLAS) showed patients with advanced non-small cell lung cancer (NSCLC) who ... mehr

30. Mai 2009
Full results from first Phase III study of Avastin in adjuvant colon cancer announced
Results suggest future trials may hold promise for Avastin as early-stage colon cancer treatment even though C-08 study does ... mehr

28. Mai 2009
New form of targeted therapy offers further hope to patients with advanced HER2-positive breast cancer
Final results from a phase II study presented at ASCO show that 25% of women with advanced HER2-positive breast cancer experienced ... mehr

27. Mai 2009
Reminder: Roche investor science event from ADA 2009
Phase II data on PPAR co-agonist aleglitazar and overall update on Roche´s diabetes & metabolic diseases pipeline mehr

26. Mai 2009
Roche Investor Science Event: Conference call from EULAR 2009
We are pleased to invite you to a Conference Call to discuss new data on our Rheumatoid Arthritis portfolio being presented ... mehr

25. Mai 2009
Reminder - Roche Investor Events: ASCO 2009
We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products ... mehr

25. Mai 2009
Two-year data reinforce effectiveness of ACTEMRA in inhibiting joint damage and improving physical function in patients with rheumatoid arthritis
Roche announced today that new two-year data from the LITHE study demonstrate that ACTEMRA (tocilizumab, known as RoACTEMRA ... mehr

20. Mai 2009
Roche ASCO planner
Roche and Genentech will present a large number of abstracts on their broad oncology portfolio at the Annual Meeting of American ... mehr

19. Mai 2009
Genentech and Biogen Idec submit applications to the FDA for Rituxan for most common type of adult leukemia
Genentech, Inc., wholly owned member of the Roche Group (SWX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) today ... mehr

19. Mai 2009
Roche Investor Events: ASCO 2009
We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products ... mehr

18. Mai 2009
Roche joins forces to innovate toxicity testing and to reduce animal experimentation
Today, Roche opened the Joint Science & Technology Laboratory in Basel, where Roche Pharma scientists are using the innovative ... mehr

15. Mai 2009
Avastin plus commonly used chemotherapies improved progression-free survival in advanced breast cancer
Data from RIBBON 1 study provides efficacy and safety information with different types of chemotherapy mehr

15. Mai 2009
Roche to present major advances with targeted cancer medicines at ASCO
More than 500 scientific abstracts to be presented across 20 types of cancers. Results could significantly improve the way ... mehr

11. Mai 2009
Roche investor science event from ADA 2009
Phase II data on PPAR co-agonist aleglitazar and overall update on Roche's diabetes & metabolic diseases pipeline mehr

06. Mai 2009
Important New Treatment Option Approved in US for Patients with the Most Aggressive Form of Brain Cancer
Roche today announced that the US Food and Drug Administration (FDA) granted accelerated approval of Avastin (bevacizumab) ... mehr

04. Mai 2009
Roche Investor Events: ASCO 2009
We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products ... mehr

30. April 2009
Roche responds to WHO move to influenza pandemic alert phase 5
Roche tonight confirms that it has been in contact with the World Health Organization (WHO) following the announcement to ... mehr

27. April 2009
Ground-breaking combination of all-oral agents demonstrates potential as hepatitis C treatment regimen
Roche (SWX: RO, ROG; OTCQX: RHHBY), InterMune, Inc. (Nasdaq: ITMN) and Pharmasset (Nasdaq: VRUS) announced the first results ... mehr

22. April 2009
Phase III C-08 study of Avastin in early-stage colon cancer does not meet primary endpoint
Roche today announced the results of the first phase III trial evaluating the use of Avastin (bevacizumab) plus chemotherapy ... mehr

16. April 2009
Roche strongly outperforms market in first quarter
Genentech transaction completed, integration proceeding rapidly mehr

15. April 2009
Reminder: Roche's First Quarter Sales 2009 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

15. April 2009
Roche Diabetes Care supports "Changing Diabetes in Children"
Roche today announced that it will join forces with Novo Nordisk and the World Diabetes Foundation (WDF) in Novo Nordisk’s ... mehr

14. April 2009
Roche and Genentech announce organizational and leadership decisions
Following the completion of the Genentech transaction Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) today announced the successful ... mehr

08. April 2009
Roche and Genentech announce voluntary withdrawal of Raptiva from the U.S. market
Roche and Genentech, Inc. announced today a phased voluntary withdrawal of the psoriasis drug Raptiva (efalizumab) from the ... mehr

07. April 2009
Presentational changes of Roche's quarterly sales results
As announced earlier, the Roche Group will publish its first quarter sales results on 16 April 2009. To reflect the Pharmaceuticals ... mehr

02. April 2009
Roche to introduce new LightCycler MRSA Advanced Test in the EU
Roche announced today that its new LightCycler test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) ... mehr

01. April 2009
FDA ADVISORY COMMITTEE UNANIMOUSLY RECOMMENDS ACCELERATED APPROVAL OF AVASTIN FOR PREVIOUSLY TREATED BRAIN CANCER (GLIOBLASTOMA)
Genentech, Inc. announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) ... mehr

31. März 2009
Avastin label updated reflecting confidence in safety profile
The European Medicines Agency (EMEA) has removed a restriction in the product label which prevented the use of Avastin (bevacizumab) ... mehr

26. März 2009
Roche completes acquisition of Genentech
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech announced today that Roche has completed its acquisition of Genentech ... mehr

26. März 2009
Roche completes tender offer for Genentech
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that its wholly-owned subsidiary, Roche Investments USA Inc., completed ... mehr

24. März 2009
RiskMetrics Group Recommends Genentech Shareholders Accept Roche's $95.00 per Share Cash Tender Offer
Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that RiskMetrics Group, Inc., a leading provider of risk and corporate ... mehr

19. März 2009
Roche announces filing of Tarceva in EU as first-line maintenance therapy in advanced non-small cell lung cancer
Today, Roche submitted an extension of the Marketing Authorisation Application to the European Medicines Agency (EMEA) for ... mehr

18. März 2009
Roche's First Quarter Sales 2009 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

18. März 2009
Herceptin now shown to significantly prolong the lives of patients with HER2-positive advanced stomach cancer
Roche today announced results from a major international study which show that adding Herceptin (trastuzumab) to standard ... mehr

12. März 2009
Roche and Genentech reach a friendly agreement to combine the two organizations and create a leader in healthcare innovation
Roche (SWX: ROG.VX; RO.S) and Genentech (NYSE: DNA) announced today that they signed a merger agreement under which Roche ... mehr

11. März 2009
Herceptin proven to benefit women with HER2 positive early breast cancer - latest results from the HERA study
The Breast International Group (BIG) in collaboration with Roche announced today that women with HER2 positive early breast ... mehr

10. März 2009
Roche Annual General Meeting: dividend raised by 9 percent
Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. ... mehr

06. März 2009
Roche increases offer price for Genentech shares to US$ 93 per share and extends offer
Roche (SWX: ROG.VX; RO.S) announced today that it has increased its offer price for all outstanding publicly-held shares of ... mehr

27. Februar 2009
Roche announces bond offerings
Roche has successfully undertaken a large offering of notes in U.S. dollars, and is completing another large offering of notes ... mehr

27. Februar 2009
MabThera approved in the EU for patients with chronic lymphocytic leukaemia
Roche announced today that the European Commission has approved MabThera (rituximab) in combination with chemotherapy for ... mehr

16. Februar 2009
Study proves longer prophylactic therapy with Valcyte increases protection against CMV - the most serious viral infection affecting transplant patients
Roche announced today that a Phase III study investigating the efficacy and safety of extended preventative therapy ('prophylaxis') ... mehr

16. Februar 2009
For the first time, doctors can predict which hepatitis B patients have the highest chance to achieve treatment success with Pegasys
New data presented today showed that, for the first time, doctors can predict which hepatitis B patients treated with Pegasys ... mehr

09. Februar 2009
Roche commences tender offer for Genentech for US$86.50 per share in cash
Roche announced today that it is commencing a cash tender offer for all outstanding publicly-held shares of Genentech for ... mehr

04. Februar 2009
Strong operating results for Roche in 2008
Double-digit sales growth – Core Earnings per share at constant exchange rates above 2007 level – Dividend increase ... mehr

03. Februar 2009
Reminder: Roche's Full Year Results for 2008
Roche will publish its Full Year Results for 2008 prior to the opening of the Swiss Stock Exchange on February 4 at 7.00 CET ... mehr

03. Februar 2009
Avastin and Tarceva in combination significantly improves the time patients with advanced lung cancer can live without their disease worsening
Roche today announced interim results from a phase III study (ATLAS) in patients with advanced non small cell lung cancer ... mehr

30. Januar 2009
Roche intends to commence tender offer to acquire all shares of Genentech for US$ 86.50 per share in cash
Roche announced today that it intends to commence a cash tender offer for all outstanding publicly-held shares of Genentech ... mehr

28. Januar 2009
Roche delighted about pool extension
Roche’s Board of Directors and Corporate Executive Committee is delighted about the extension of the shareholders’ ... mehr

28. Januar 2009
MabThera filed in the EU for treatment of relapsed or refractory chronic lymphocytic leukaemia
Roche today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) ... mehr

23. Januar 2009
MabThera receives positive opinion in Europe for first-line treatment for chronic lymphocytic leukaemia
Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation ... mehr

21. Januar 2009
Reminder: Roche's Full Year Results for 2008
Roche will publish its Full Year Results for 2008 prior to the opening of the Swiss Stock Exchange on February 4 at 7.00 ... mehr

21. Januar 2009
RoACTEMRA approved in Europe to treat patients suffering from Rheumatoid Arthritis
Roche today announced that the European Commission has approved RoACTEMRA (tocilizumab, known as Actemra outside of the EU), ... mehr

05. Januar 2009
Roche's Full Year Results for 2008
4 February – 8.00 CET – Morning Telephone Conference 4 February - 15.00 GMT - Presentation in London (16.00 CET) 6 ... mehr

05. Januar 2009
Roche Purchases Shares in Tender Offer for Memory Pharmaceuticals Corp.
Roche (SWX: ROG.VX; RO.S; OTCQX; RHHBY) today announced that its wholly-owned subsidiary 900 North Point Acquisition Corporation ... mehr

19. Dezember 2008
Roche announces update to its U.S. ADR facility
As of today, Roche's American Depositary Receipt (ADR) program (OTCQX: RHHBY) has moved from The Bank of New York Mellon ... mehr

19. Dezember 2008
MabThera inhibits the destruction of joints in patients with early rheumatoid arthritis
Roche announced today that the radiographic IMAGE study investigating MabThera (rituximab) in combination with methotrexate ... mehr

16. Dezember 2008
Avastin filed in Europe for treatment of patients with the most aggressive form of brain cancer
Roche announced today the filing of its anti-angiogenic cancer treatment Avastin (bevacizumab) for the treatment of patients ... mehr

15. Dezember 2008
Xeloda shows strong promise in early breast cancer
Data presented at the San Antonio Breast Cancer Symposium (SABCS) indicate that adding Xeloda to standard chemotherapy allows ... mehr

11. Dezember 2008
Herceptin given prior to surgery improves the chance of survival without relapse for women with HER2-positive breast cancer
About 70% of women with locally advanced HER2-positive breast cancer were free of their disease three years after initiation ... mehr

10. Dezember 2008
New data show that Herceptin, Xeloda and Avastin help patients with early and advanced breast cancer live longer or remain disease free for longer
New data being presented at the 31st Annual San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), ... mehr

10. Dezember 2008
MabThera maintenance therapy in lymphoma patients stops cancer coming back for nearly three times as long as chemotherapy alone
New data presented at the 50th Annual Meeting of the American Society of Hematology (ASH) confirm that patients with recurrent ... mehr

09. Dezember 2008
First glyco-engineered and humanized monoclonal antibody in clinical trials could offer hope for difficult to treat lymphoma patients
Roche shows promising early results for its third-generation monoclonal antibody for CD20-positive hematological malignancies mehr

08. Dezember 2008
Reminder: Invitation to Roche investor science event from ASH 2008
We kindly invite investors and analysts to participate in a conference call to discuss new clinical data and results presented ... mehr

08. Dezember 2008
New phase III data suggest MabThera is a highly effective treatment for patients with idiopathic thrombocytopenic purpura
New data presented at the 50th Annual Meeting of the American Society of Hematology (ASH) today show that people living with ... mehr

07. Dezember 2008
New data show MabThera enables leukemia patients to live longer without their disease progressing
New data from two pivotal phase III studies to be presented at the Annual Meeting of the American Society of Hematology in ... mehr

04. Dezember 2008
Roche and FDA Agree on Pathway Towards U.S. Approval of ACTEMRA (tocilizumab)
Roche today announced that the U.S. Food and Drug Administration (FDA) has provided further guidance on the requirements for ... mehr

04. Dezember 2008
European Commission approval of new indication for Roche’s Pegasys offers hepatitis C patients a second chance for a cure
Roche announced today that the European Commission has approved Pegasys (peginterferon alfa-2a [40 KD]) plus Copegus (ribavirin) ... mehr

26. November 2008
Anti-malignancy agent / anti-VEGF humanised monoclonal antibody, Avastin Application for Approval of Additional Indication of NSCLC
Chugai Pharmaceutical Co., Ltd. announced today that the company filed an application with the Japanese Ministry of Health, ... mehr

25. November 2008
Roche signs definitive agreement to acquire Memory Pharmaceuticals
Roche and Memory Pharmaceuticals today announced that the two companies have signed a definitive merger agreement for Roche ... mehr

24. November 2008
Avastin verlängert die Überlebenszeit von Patientinnen mit fortgeschrittenem Brustkrebs ohne Fortschreiten der Krankheit
Dritte Studie, die den Nutzen von Avastin bei der Behandlung von Brustkrebs bestätigt und zeigt, dass Avastin mit Chemotherapien ... mehr

21. November 2008
RoActemra Receives Positive Opinion in Europe for the Treatment of Rheumatoid Arthritis
Roche today announced that the European Committee on Human Medicinal Products (CHMP) has given a positive recommendation for ... mehr

21. November 2008
Study of MabThera in the most common form of adult leukaemia selected as late-breaking abstract for the ASH annual meeting
Roche announced today that full results of the pivotal REACH study will be presented as part of the late breaker abstract ... mehr

14. November 2008
Tarceva-Avastin combination doubles time that patients with advanced lung cancer live without their disease progressing
Results of the phase III BeTa Lung study investigating the addition of Avastin (bevacizumab) to Tarceva (erlotinib) for the ... mehr

13. November 2008
Avastin gives an additional 4 months of life to patients with one of the most common types of lung cancer
Roche announced today that an exploratory analysis of the pivotal phase III E4599 study demonstrated that Avastin (bevacizumab) ... mehr

10. November 2008
Invitation to Roche investor science event from ASH 2008 - Conference call on 9 December 2008
We kindly invite investors and analysts to participate in a conference call to discuss new clinical data and results presented ... mehr

07. November 2008
Tarceva brings new hope to patients with advanced non-small cell lung cancer
Roche today announced that the SATURN (SequentiAl Tarceva in UnResectable NSCLC) study met its primary endpoint of progression ... mehr

03. November 2008
Avastin filed in U.S. for treatment of patients with the most aggressive form of brain cancer
Roche announced today that its U.S. partner Genentech submitted a supplemental Biologics License Application (sBLA) to the ... mehr

03. November 2008
Renewed hope for a cure: Extending Pegasys treatment to 72 weeks provides new treatment option for difficult-to-treat hepatitis C patients
Three new studies presented at AASLD demonstrate efficacy and safety of extended treatment in non-responders, relapsers and ... mehr

03. November 2008
New study shows that Pegasys provides higher cure rates for hepatitis C patients
A new, independently conducted study presented at the American Association for the Study of Liver Disease conference, AASLD, ... mehr

27. Oktober 2008
Study shows MabThera continues to improve patient response in rheumatoid arthritis with multiple courses of treatment
A study has shown that rheumatoid arthritis patients given multiple courses of MabThera experienced further improvements in ... mehr

27. Oktober 2008
New data shows ACTEMRA inhibits progression of joint destruction and improves physical function of patients with Rheumatoid Arthritis
Roche announced today that the innovative new therapy ACTEMRA (tocilizumab) can significantly inhibit structural damage to ... mehr

20. Oktober 2008
Variety of studies on Roche's Rheumatoid Arthritis portfolio to be presented at the American College of Rheumatology Annual Scientific Meeting
Roche today announced that a total of 15 abstracts involving its investigational rheumatoid arthritis (RA) treatment Actemra ... mehr

20. Oktober 2008
Reminder: Roche's Third Quarter Sales 2008 Conference Call Tuesday October 21st, 2008
Roche will publish its Sales Results for the 3rd Quarter of 2008 prior to the opening of the Swiss Stock Exchange on Tuesday ... mehr

07. Oktober 2008
Pivotal Phase III study shows MabThera delays disease progression in patients with relapsed or refractory Chronic Lymphocytic Leukaemia
Roche announced today that a Phase III study investigating MabThera (rituximab) in combination with chemotherapy has shown ... mehr

06. Oktober 2008
Roche announces topline outcomes for Avastin-Tarceva combination study in advanced lung cancer
Phase III data shows evidence of potential benefit for patients with advanced lung cancer. Roche today announced topline results ... mehr

03. Oktober 2008
Genentech, Glycart and Roche enter into collaboration agreement for potential cancer therapy
Genentech, Inc. (NYSE: DNA), GlycArt, a company wholly-owned by Roche, and Roche (SWX: ROG) have entered into a collaboration ... mehr

02. Oktober 2008
Actemra significantly improves the debilitating symptoms of Rheumatoid Arthritis in patients who do not adequately respond to standard therapies
The innovative rheumatoid arthritis drug Actemra (tocilizumab) has been shown to significantly improve the signs and symptoms ... mehr

22. September 2008
Roche's Third Quarter Sales 2008 Conference Call Tuesday October 21st, 2008
Roche will publish its Sales Results for the 3rd Quarter of 2008 prior to the opening of the Swiss Stock Exchange on Tuesday ... mehr

18. September 2008
FDA issues complete response letter to Roche for Actemra Biologics License Application
Roche today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the Biologics ... mehr

16. September 2008
Avastin: only biologic to demonstrate significant survival benefit in first-line and second-line metastatic colorectal cancer patients
Data presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) confirmed that Avastin in combination ... mehr

15. September 2008
Final analysis of Phase III trial confirms benefit of Avastin in Lung cancer
The final analysis of the pivotal phase III Roche-sponsored AVAiL (Avastin in lung) study in patients with previously untreated, ... mehr

15. August 2008
Roche and the wider global community: making a lasting difference to people’s lives
Progress report on new initiatives in providing Access to Medicine and encouraging scientists mehr

15. August 2008
Roche und Meda vereinbaren Übernahme von Produkten
Veräusserung von vier Medikamenten verstärkt Fokussierung von Roche auf Kern- Therapiegebiete mehr

31. Juli 2008
Full reconciliation of Chugai interim results into IFRS
Results of Chugai as consolidated by the Roche Group mehr

31. Juli 2008
Toll Manufacturing Agreement for the Bulk Drug Substance of Actemra, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody
Please find enclosed a press release by Chugai. mehr

31. Juli 2008
MabThera filed in the EU for treatment of most common leukaemia in adults
Submission based on Phase III study showing superior results for MabThera in Chronic Lymphocytic Leukaemia (CLL) when added ... mehr

30. Juli 2008
FDA Advisory Committee recommends approval of Actemra for the treatment of rheumatoid arthritis
Roche announced that the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) by a near unanimous (10-1) ... mehr

28. Juli 2008
Avastin filed for broader breast cancer label in Europe
Roche announced today that they have submitted an application to the EMEA to extend the current European label of Avastin ... mehr

23. Juli 2008
Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
Roche und ARIUS Research Inc. gaben heute bekannt, dass die beiden Unternehmen eine definitive Vereinbarung unterzeichnet ... mehr

22. Juli 2008
Reminder: Roche Investor Events: AACC 2008
mehr

21. Juli 2008
Roche posts very good results: strong market outperformance - guidance confirmed
mehr

21. Juli 2008
Roche makes offer to acquire all outstanding shares of Genentech for US $89.00 per share in cash
Combination to enhance innovation by allowing for diversity of research approaches while also encouraging sharing of IP, technologies, ... mehr

20. Juli 2008
Roche Half-Year Results 2008 brought forward to Monday, 21 July 2008
We wish to inform you that the Half-Year Results for 2008 will now be published prior to opening of the Swiss Stock exchange ... mehr

02. Juli 2008
Roche Investor Events: AACC 2008
mehr

30. Juni 2008
Avastin shows unprecedented benefits in colorectal cancer patients, irrespective of K-Ras gene mutation
Data presented today at the 10th World Congress on Gastrointestinal Cancer (WCGC) in Barcelona confirm that Avastin (bevacizumab) ... mehr

27. Juni 2008
Roche's Half Year Results for 2008
Roche will publish its Half Year Results for 2008 prior to the opening of the Swiss Stock Exchange on July 24 at 7.00 CET ... mehr

27. Juni 2008
Introducing Roche's new Finance Information System
Roche today announced that it has launched on its Investor Relations homepage an innovative online tool to facilitate and ... mehr

26. Juni 2008
European approval for Roche`s Pegasys personalises treatment for a subgroup of hepatitis C patients: chance for cure with only four months of treatment
mehr

24. Juni 2008
Erfolgreicher Abschluss der Tender Offer: Roche erhöht ihre Beteiligung an Chugai
Roche gab heute bekannt, dass sie ihre Beteiligung an Chugai von 50,1% auf 59,9% erhöhen wird. Dies folgt dem erfolgreichen ... mehr

13. Juni 2008
New data reveals Actemra is the first and only biologic drug to show superiority over current standard of care in rheumatoid arthritis
mehr

11. Juni 2008
New evidence shows MabThera is more effective than a second TNF inhibitor in rheumatoid arthritis patients who have interrupted anti-TNF therapy due to lack of efficacy
New data also proves MabThera’s inhibition of joint damage is maintained over two years mehr

10. Juni 2008
Roche moves investigational diabetes drug, Taspoglutide, into Phase III clinical trials
Positive Phase II results of Roche and Ipsen’s first once-weekly human GLP-1 presented at the American Diabetes Association ... mehr

06. Juni 2008
Roche Investor Science Event: EULAR 2008
nvitation to Roche’s analyst briefing on Actemra and MabThera Friday, June 13th 2008 in Paris mehr

04. Juni 2008
Significant new data on Roche’s Rheumatoid Arthritis portfolio to be presented at the EULAR Annual Meeting 2008
mehr

02. Juni 2008
Reminder: Invitation to Roche investor science event - phase IIb data on R1583 GLP-1 analogue and overall update on Roche's franchise in diabetes & metabolism Monday, 9 June 2008
We kindly invite investors and analysts to participate in an event to present and discuss new phase IIb data and results on ... mehr

31. Mai 2008
Studie bestätigt: Avastin erhöht bei metastasierendem Brustkrebs signifikant die Überlebenschancen ohne Fortschreiten der Krankheit
Avastin (Bevacizumab) - in Kombination mit der standardmässig verwendeten Chemotherapie Docetaxel (Taxotere) - führt ... mehr

31. Mai 2008
Benefits of Avastin in metastatic colorectal cancer further substantiated
A wealth of new Avastin (bevacizumab) data were presented at the 44th Annual Meeting of the American Society of Clinical Oncology ... mehr

30. Mai 2008
Pertuzumab with Herceptin shows impressive results in women with advanced HER2-positive breast cancer
New data from a Phase II trial presented at the American Society of Clinical Oncology (ASCO) 2008 meeting in Chicago show ... mehr

23. Mai 2008
Reminder - Roche Science Events: ASCO 2008 - Analyst briefings on data presented at ASCO
We are pleased to invite you to our Analyst briefings to discuss data presented by Roche at the American Society of Clinical ... mehr

22. Mai 2008
Roche will Beteiligung an Chugai von 50,1% auf 59,9% erhöhen
Roche beabsichtigt, ihre Beteiligung an Chugai von heute 50,1% auf 59,9% zu erhöhen. Zu diesem Zweck macht Roche den ... mehr

20. Mai 2008
Roche Investor Science Event EULAR 2008
Invitation to Roche`s analyst briefing on Actemra and MabThera -Friday, June 13th 2008 in Paris mehr

20. Mai 2008
Roche ASCO planner
Roche and its collaborators will present a large number of abstracts on its broad oncology portfolio at the Annual Meeting ... mehr

16. Mai 2008
New Roche data to be presented at ASCO offers further hope for cancer patients
mehr

16. Mai 2008
Invitation to Roche investor science event - phase IIb data on R1583 GLP-1 analogue and overall update on Roche´s franchise in diabetes & metabolism
We kindly invite investors and analysts to participate in an event to present and discuss new phase IIb data and results on ... mehr

16. Mai 2008
Genentech provides update on Avastin Program
Overview provided for studies to be presented at the 2008 American Society of Clinical Oncology Annual Meeting; and updated ... mehr

09. Mai 2008
Actemra hemmt Gelenkschäden und verbessert körperliche Leistungsfähigkeit bei Patienten mit rheumatoider Arthritis
Roche gab heute Ergebnisse bekannt, die zeigen, dass Actemra (Tocilizumab) bei Patienten mit rheumatoider Arthritis (RA) strukturelle ... mehr

05. Mai 2008
Roche Science Events: ASCO 2008
We are pleased to invite you to our Analyst briefings to discuss data presented by Roche at the American Society of Clinical ... mehr

29. April 2008
Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Genentech and Biogen Idec announced today top-line results from a phase II/III clinical study of Rituxan in Systemic Lupus ... mehr

28. April 2008
Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C
Roche today announced that compelling new data from three studies indicate that chronic hepatitis C patients who received ... mehr

28. April 2008
Roche`s R1626, First-in-Class Hepatitis C Polymerase Inhibitor, Demonstrates Impressive End-of-Treatment Response in Phase IIa Study
Roche`s investigational treatment for hepatitis C, R1626, has shown an impressive end-of-treatment response rate when given ... mehr

21. April 2008
Roche provides update on a phase III study (AVAiL) of Avastin plus chemotherapy in first-line, advanced, non-squamous, non-small cell lung cancer
Roche today announced an update of the previously reported phase III clinical study (AVAiL) of Avastin (bevacizumab), which ... mehr

18. April 2008
Herceptin helps eradicate HER2-positive breast tumours when given before surgery
New data presented today as part of a late breaking plenary session at EBCC in Berlin showed that Herceptin (trastuzumab) ... mehr

17. April 2008
Roche setzt Verkaufsdynamik im ersten Quartal 2008 fort - beide Divisionen wachsen signifikant schneller als der Markt
Zweistellige Zuwächse bei Schlüsselprodukten machen einmalige Tamiflu-Grossaufträge des Vorjahres mehr als ... mehr

16. April 2008
Reminder: Roche`s First Quarter Sales 2008 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2008 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

16. April 2008
Actemra in Japan für die Behandlung von rheumatoider Arthritis zugelassen
Roche gab heute bekannt, dass ihr Partnerunternehmen Chugai in Japan die Zulassung für die Anwendung ihres innovativen ... mehr

15. April 2008
Roche übernimmt das Biotechnologie-Unternehmen Piramed
Roche übernimmt Piramed Limited, ein britisches Unternehmen, das sich auf Therapien konzentriert, die gezielt an der ... mehr

01. April 2008
InterMune announces top-line results of phase 1b trial of itmn-191 (R7227) and provides program update
InterMune, Inc. (Nasdaq: ITMN) today provided an overall program update and reported the top-line results from the four dose ... mehr

01. April 2008
Phase II pooled safety results of Roche's investigational CETP inhibitor presented at the American College of Cardiology
mehr

31. März 2008
Reminder: Roche Science Event - Conference Call from ACC
mehr

25. März 2008
Roche`s First Quarter Sales 2008 Conference Call
Roche will publish its Sales Results for the 1st Quarter of 2008 prior to the opening of the Swiss Stock Exchange on Thursday ... mehr

25. März 2008
Novel drug ACTEMRA significantly improves the debilitating symptoms of Rheumatoid Arthritis in patients who have an inadequate response to standard therapy
mehr

17. März 2008
Roche Science Event Conference Call from ACC
We are pleased to invite you to a Conference Call discussing data on Roche`s CETP inhibitor R1658 presented at the American ... mehr

04. März 2008
Roche erhöht Dividende um 35 Prozent
Generalversammlung genehmigt Jahresbericht und Jahresrechnung 2007 mehr

29. Februar 2008
Combination therapy of anti-cancer agents Xeloda, oxaliplatin and Avastin, and Xeloda monotherapy filed for advanced or recurrent colorectal cancer in Japan
Chugai Pharmaceutical Co. announced today that it filed an application with the Japanese Ministry of Health, Labour and Welfare ... mehr

29. Februar 2008
Herceptin wird in Japan zur Frühbehandlung von HER2-positivem Brustkrebs zugelassen
Chugai Pharmaceutical Co., Ltd., an der Roche eine Mehrheitsbeteiligung hält, hat von der japanischen Gesundheitsbehörde ... mehr

25. Februar 2008
FDA grants accelerated approval of Avastin in combination with paclitaxel chemotherapy for first-line treatment of patients with advanced HER2-negative breast cancer
Roche today announced that Genentech has received U.S. Food and Drug Administration (FDA) accelerated approval for Avastin® ... mehr

19. Februar 2008
Roche schliesst Übernahmeangebot für Ventana-Aktien ab
Wie heute von Roche (SWX: ROG.VX; RO.S; OTCQX; RHHBY) und Ventana Medical Systems Inc. (NASDAQ: VMSI) bekannt gegeben, hat ... mehr

13. Februar 2008
Zweite Phase-III-Studie mit Avastin zur Erstbehandlung von metastasierendem Brustkrebs erreicht primären Endpunkt
Eine Phase-III-Studie mit dem Roche-Medikament Avastin (Bevacizumab) hat ihren primären Endpunkt erreicht: Die Studie ... mehr

08. Februar 2008
Roche erwirbt Aktien im Übernahmeangebot für Ventana
Roche gab heute bekannt, dass ihre Tochter Rocket Acquisition Corporation alle entsprechend ihres Übernahmeangebots für ... mehr

04. Februar 2008
EU Grants Broad Approval of Xeloda for Patients with Metastatic Colorectal Cancer
Roche announced today that the European Commission has approved its oral chemotherapy Xeloda (capecitabine) for the treatment ... mehr

30. Januar 2008
Roche erreicht 2007 erneut operatives Rekordergebnis
Gewinnwachstum pro Titel doppelt so hoch wie Umsatzzunahme - Umsatzsteigerung im siebten Jahr in Folge zweistellig - Markante ... mehr

29. Januar 2008
Reminder: Roche`s Full Year Results and Report for 2007
Roche will publish its Full Year Results for 2007 prior to the opening of the Swiss Stock Exchange at 7.00 CET / 6.00 GMT ... mehr

28. Januar 2008
In Europa erhebliche Zulassungserweiterung für Avastin in der Behandlung des metastasierenden Kolorektalkarzinoms (Dickdarmkrebses)
Jetzt können deutlich mehr Patienten vom nachgewiesenen Überlebensvorteil durch Avastin profitieren. Roche gab heute ... mehr

25. Januar 2008
MabThera verlängert bei Patienten mit der im Erwachsenenalter häufigsten Leukämieform die Überlebenszeit ohne Fortschreiten des Blutkrebses
Zulassungsrelevante Phase-III-Studie mit MabThera erreicht den primären Endpunkt in der Erstlinienbehandlung bei Patienten ... mehr

25. Januar 2008
MabThera erreicht primären Endpunkt: Verbesserung der Krankheitssymptome bei Anwendung als biologische Erstlinienbehandlung bei rheumatoider Arthritis
Phase-III-Studie zeigt erstmalig Potenzial von MabThera beim frühzeitigeren Einsatz im Therapieverlauf. Roche gab heute ... mehr

22. Januar 2008
Roche übernimmt Ventana für US$ 89,50 je Aktie
Roche und Ventana unterzeichnen endgültige Übernahmevereinbarung mehr

16. Januar 2008
Reminder: Roche`s Full Year Results and Report for 2007
Roche will publish its Full Year Results for 2007 prior to the opening of the Swiss Stock Exchange at 7.00 CET / 6.00 GMT ... mehr

08. Januar 2008
Pharmasset announces R7128 achieves 85% rapid virologic response in a 4-week combination study for the treatment of chronic hepatitic C
Pharmasset announced today the preliminary results of a 4-week Phase 1 clinical trial to evaluate two oral dose levels of ... mehr